Previous 10 | Next 10 |
home / stock / dmttf / dmttf news
LONDON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Mr. Peter Rands disposed of an aggregate of 1,532,001 common shares in the capital of Small Pharma Inc. (the “ Company ”) between September 25, 2023 and September 27, 2023 at an average price of $0.177 per common share for aggregate proc...
2023-09-29 10:00:00 ET More on psychedelic drugs Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies With ecstasy a potential PTSD therapy, psychedelic treatments could take off Psychedelic Stocks = Super-Risky Biote...
• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs • At Week 4, 100% of patients in the SSRI cohort responded to SPL026 (DMT) with 92% of patients in remission from depres...
2023-08-28 11:18:10 ET More on Cybin, Small Pharma Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. Psychedelic Stocks: Don't Bet On Just 1 Company Cybin renews $35M ATM equity offering Cybin stock falls on pricing discounted stock and ...
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics - - Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy - - Combined portfolio creates the indust...
• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an expedited route to an international, multi-site Phase II study with SPL028 in 2024, based on clinical findings across SPL026 and SPL028 programs to date ...
2023-07-05 07:34:29 ET Biotechnology company Small Pharma ( TSXV: DMT:CA ) ( OTCQB:DMTTF ) said on Wednesday that Peter Rands, co-founder, chief innovation and intellectual property officer and former CEO, has left his executive positions and directorship, effective July ...
• Preliminary findings from ongoing Phase I trial of second-generation DMT asset SPL028 indicate the potential for a unique therapeutic profile • Proof-of-concept data from Company’s native DMT program, SPL026, offers potential for an expedited rou...
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that Mr. P...
LONDON, May 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update...
News, Short Squeeze, Breakout and More Instantly...
2024-03-27 17:08:02 ET The world is facing a mental health crisis. Today, one in six individuals are likely to suffer from an episode of major depression during their lifetime that could significantly impact their relationships, work and health. Add to that the substantial negative impact t...
2024-03-27 17:08:02 ET Help for mental health sufferers Small Pharma is a neuropharmaceutical company. They specialize in IP led development of novel treatments for mental health conditions, with a focus on depression. Small Pharma initiated a clinical program into DMT-assiste...
Cybin (NYSE American: CYBN) (NEO: CYBN) together with Small Pharma Inc. (TSX.V: DMT) (OTCQB: DMTTF) announced the completion of the previously disclosed acquisition by Cybin of Small Pharma by way of a plan of arrangement under the Business Corporations Act (British Columbia), and pursuant to ...